125 related articles for article (PubMed ID: 38181584)
21. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death.
Zahid KR; Han S; Zhou F; Raza U
Cell Oncol (Dordr); 2019 Feb; 42(1):55-66. PubMed ID: 30238408
[TBL] [Abstract][Full Text] [Related]
22. PIN1 in hepatocellular carcinoma is associated with TP53 gene status.
Bae JS; Noh SJ; Kim KM; Jang KY; Park HS; Chung MJ; Park BH; Moon WS
Oncol Rep; 2016 Oct; 36(4):2405-11. PubMed ID: 27499097
[TBL] [Abstract][Full Text] [Related]
23. Overexpression of Uric Acid Transporter SLC2A9 Inhibits Proliferation of Hepatocellular Carcinoma Cells.
Han X; Yang J; Li D; Guo Z
Oncol Res; 2019 May; 27(5):533-540. PubMed ID: 29523220
[TBL] [Abstract][Full Text] [Related]
24. TPX2 silencing exerts anti‑tumor effects on hepatocellular carcinoma by regulating the PI3K/AKT signaling pathway.
Huang DH; Jian J; Li S; Zhang Y; Liu LZ
Int J Mol Med; 2019 Dec; 44(6):2113-2122. PubMed ID: 31638175
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Protein Phosphatase 1γ (PP1γ) Is Associated with Enhanced Cell Proliferation and Poor Prognosis in Hepatocellular Carcinoma.
Li C; Wu M; Zong G; Wan C; Liu Q; Zhou H; Hua L; Chen Y; Chen X; Lu C
Dig Dis Sci; 2017 Jan; 62(1):133-142. PubMed ID: 27921263
[TBL] [Abstract][Full Text] [Related]
26. Regulatory factor X5 promotes hepatocellular carcinoma progression by transactivating tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein theta and suppressing apoptosis.
Chen DB; Zhao YJ; Wang XY; Liao WJ; Chen P; Deng KJ; Cong X; Fei R; Wu X; Shao QX; Wei L; Xie XW; Chen HS
Chin Med J (Engl); 2019 Jul; 132(13):1572-1581. PubMed ID: 31188160
[TBL] [Abstract][Full Text] [Related]
27. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
[TBL] [Abstract][Full Text] [Related]
28. Tigecycline causes loss of cell viability mediated by mitochondrial OXPHOS and RAC1 in hepatocellular carcinoma cells.
Koch DT; Yu H; Beirith I; Schirren M; Drefs M; Liu Y; Knoblauch M; Koliogiannis D; Sheng W; De Toni EN; Bazhin AV; Renz BW; Guba MO; Werner J; Ilmer M
J Transl Med; 2023 Dec; 21(1):876. PubMed ID: 38041179
[TBL] [Abstract][Full Text] [Related]
29. LAGE3 promoted cell proliferation, migration, and invasion and inhibited cell apoptosis of hepatocellular carcinoma by facilitating the JNK and ERK signaling pathway.
Xing Y; Liu Y; Qi Z; Liu Z; Wang X; Zhang H
Cell Mol Biol Lett; 2021 Nov; 26(1):49. PubMed ID: 34837962
[TBL] [Abstract][Full Text] [Related]
30. Growth arrest-specific gene 2 suppresses hepatocarcinogenesis by intervention of cell cycle and p53-dependent apoptosis.
Zhu RX; Cheng ASL; Chan HLY; Yang DY; Seto WK
World J Gastroenterol; 2019 Aug; 25(32):4715-4726. PubMed ID: 31528096
[TBL] [Abstract][Full Text] [Related]
31. Involvement of phorbol-12-myristate-13-acetate-induced protein 1 in goniothalamin-induced TP53-dependent and -independent apoptosis in hepatocellular carcinoma-derived cells.
Kuo KK; Chen YL; Chen LR; Li CF; Lan YH; Chang FR; Wu YC; Shiue YL
Toxicol Appl Pharmacol; 2011 Oct; 256(1):8-23. PubMed ID: 21810437
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.
Ishibashi M; Kogo R; Shibata K; Ueo H; Uchi R; Matsumura T; Takano Y; Sawada G; Takahashi Y; Mima K; Kurashige J; Akiyoshi S; Iwaya T; Eguchi H; Sudo T; Sugimachi K; Suzuki A; Wakabayashi G; Mori M; Mimori K
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S537-44. PubMed ID: 23532381
[TBL] [Abstract][Full Text] [Related]
33. H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro.
Luo M; Xiong Y; Lin Y; Liang R; Li Y; Ge L
Med Sci Monit; 2021 May; 27():e930215. PubMed ID: 33990536
[TBL] [Abstract][Full Text] [Related]
34. Upregulated TRIO expression correlates with a malignant phenotype in human hepatocellular carcinoma.
Wang B; Fang J; Qu L; Cao Z; Zhou J; Deng B
Tumour Biol; 2015 Sep; 36(9):6901-8. PubMed ID: 25851347
[TBL] [Abstract][Full Text] [Related]
35. miR-1307-3p promotes tumor growth and metastasis of hepatocellular carcinoma by repressing DAB2 interacting protein.
Chen S; Wang L; Yao B; Liu Q; Guo C
Biomed Pharmacother; 2019 Sep; 117():109055. PubMed ID: 31176165
[TBL] [Abstract][Full Text] [Related]
36. Knockdown of PSMC3IP suppresses the proliferation and xenografted tumorigenesis of hepatocellular carcinoma cell.
Ding J; Li Y; Fan H; Xu W; Gao R; Bai S; Zhu Z; Yang W; Gong Y; Yang J; Zhou J
J Cell Biochem; 2019 Apr; 120(4):5449-5458. PubMed ID: 30362169
[TBL] [Abstract][Full Text] [Related]
37. lncRNA HOXB-AS3 promotes hepatoma by inhibiting p53 expression.
Zhang XM; Chen H; Zhou B; Zhang QY; Liao Y; Wang JS; Wang ZH
Eur Rev Med Pharmacol Sci; 2018 Oct; 22(20):6784-6792. PubMed ID: 30402841
[TBL] [Abstract][Full Text] [Related]
38. SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.
Zhao J; Wozniak A; Adams A; Cox J; Vittal A; Voss J; Bridges B; Weinman SA; Li Z
J Exp Clin Cancer Res; 2019 Jun; 38(1):252. PubMed ID: 31196136
[TBL] [Abstract][Full Text] [Related]
39. SPAG5 promotes hepatocellular carcinoma progression by downregulating SCARA5 through modifying β-catenin degradation.
Liu H; Hu J; Wei R; Zhou L; Pan H; Zhu H; Huang M; Luo J; Xu W
J Exp Clin Cancer Res; 2018 Sep; 37(1):229. PubMed ID: 30249289
[TBL] [Abstract][Full Text] [Related]
40. LncRNA DHRS4-AS1 ameliorates hepatocellular carcinoma by suppressing proliferation and promoting apoptosis via miR-522-3p/SOCS5 axis.
Zhou Y; Li K; Zou X; Hua Z; Wang H; Bian W; Wang H; Chen F; Dai T
Bioengineered; 2021 Dec; 12(2):10862-10877. PubMed ID: 34666613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
